BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Röhrich M, Naumann P, Giesel FL, Choyke PL, Staudinger F, Wefers A, Liew DP, Kratochwil C, Rathke H, Liermann J, Herfarth K, Jäger D, Debus J, Haberkorn U, Lang M, Koerber SA. Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas. J Nucl Med 2021;62:779-86. [PMID: 33097632 DOI: 10.2967/jnumed.120.253062] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Safi SA, Rehders A, Haeberle L, Fung S, Lehwald N, Esposito I, Ziayee F, Krieg A, Knoefel WT, Fluegen G. Para-aortic lymph nodes and ductal adenocarcinoma of the pancreas: Distant neighbors? Surgery 2021:S0039-6060(21)00666-8. [PMID: 34392977 DOI: 10.1016/j.surg.2021.06.045] [Reference Citation Analysis]
2 Shou Y, Xue Q, Yuan J, Zhao J. 68Ga-FAPI-04 PET/MR is helpful in differential diagnosis of pancreatitis from pancreatic malignancy compared to 18F-FDG PET/CT: a case report. Eur J Hybrid Imaging 2021;5:12. [PMID: 34181149 DOI: 10.1186/s41824-021-00106-1] [Reference Citation Analysis]
3 Liermann J, Syed M, Ben-Josef E, Schubert K, Schlampp I, Sprengel SD, Ristau J, Weykamp F, Röhrich M, Koerber SA, Haberkorn U, Debus J, Herfarth K, Giesel FL, Naumann P. Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer. Cancers (Basel) 2021;13:796. [PMID: 33672893 DOI: 10.3390/cancers13040796] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Montemagno C, Cassim S, De Leiris N, Durivault J, Faraggi M, Pagès G. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine? Int J Mol Sci 2021;22:6413. [PMID: 34203923 DOI: 10.3390/ijms22126413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Serfling SE, Hartrampf PE, Zhi Y, Higuchi T, Rowe SP, Bundschuh L, Essler M, Buck AK, Bundschuh RA, Werner RA. Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and Therapy. Clin Nucl Med 2022. [PMID: 35439187 DOI: 10.1097/RLU.0000000000004189] [Reference Citation Analysis]
6 van Dam MA, Vuijk FA, Stibbe JA, Houvast RD, Luelmo SAC, Crobach S, Shahbazi Feshtali S, de Geus-Oei LF, Bonsing BA, Sier CFM, Kuppen PJK, Swijnenburg RJ, Windhorst AD, Burggraaf J, Vahrmeijer AL, Mieog JSD. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. Cancers (Basel) 2021;13:6088. [PMID: 34885196 DOI: 10.3390/cancers13236088] [Reference Citation Analysis]
7 Dendl K, Schlittenhardt J, Staudinger F, Kratochwil C, Altmann A, Haberkorn U, Giesel FL. The Role of Fibroblast Activation Protein Ligands in Oncologic PET Imaging. PET Clin 2021;16:341-51. [PMID: 34053578 DOI: 10.1016/j.cpet.2021.03.012] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Ghidini M, Vuozzo M, Galassi B, Mapelli P, Ceccarossi V, Caccamo L, Picchio M, Dondossola D. The Role of Positron Emission Tomography/Computed Tomography (PET/CT) for Staging and Disease Response Assessment in Localized and Locally Advanced Pancreatic Cancer. Cancers (Basel) 2021;13:4155. [PMID: 34439307 DOI: 10.3390/cancers13164155] [Reference Citation Analysis]
9 Rowe SP, Pomper MG. Molecular imaging in oncology: Current impact and future directions. CA Cancer J Clin 2021. [PMID: 34902160 DOI: 10.3322/caac.21713] [Reference Citation Analysis]
10 Hesterberg AB, Rios BL, Wolf EM, Tubbs C, Wong HY, Schaffer KR, Lotan TL, Giannico GA, Gordetsky JB, Hurley PJ. A distinct repertoire of cancer-associated fibroblasts is enriched in cribriform prostate cancer. J Pathol Clin Res 2021;7:271-86. [PMID: 33600062 DOI: 10.1002/cjp2.205] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Aime S, Al-Qahtani M, Behe M, Bormans G, Carlucci G, DaSilva JN, Decristoforo C, Duatti A, Elsinga PH, Kopka K, Li XG, Liu Z, Mach RH, Middel O, Passchier J, Patt M, Penuelas I, Rey A, Scott PJH, Todde S, Toyohara J, Vugts D, Yang Z. Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharm Chem 2021;6:13. [PMID: 33738618 DOI: 10.1186/s41181-021-00128-x] [Reference Citation Analysis]
12 Zhang Z, Jia G, Pan G, Cao K, Yang Q, Meng H, Yang J, Zhang L, Wang T, Cheng C, Zuo C. Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 2022. [PMID: 35243518 DOI: 10.1007/s00259-022-05729-5] [Reference Citation Analysis]
13 Tatekawa S, Ofusa K, Chijimatsu R, Vecchione A, Tamari K, Ogawa K, Ishii H. Methylosystem for Cancer Sieging Strategy. Cancers (Basel) 2021;13:5088. [PMID: 34680237 DOI: 10.3390/cancers13205088] [Reference Citation Analysis]
14 Kuyumcu S, Sanli Y, Subramaniam RM. Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management. Front Oncol 2021;11:758958. [PMID: 34858834 DOI: 10.3389/fonc.2021.758958] [Reference Citation Analysis]
15 Imlimthan S, Moon ES, Rathke H, Afshar-Oromieh A, Rösch F, Rominger A, Gourni E. New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress. Pharmaceuticals (Basel) 2021;14:1023. [PMID: 34681246 DOI: 10.3390/ph14101023] [Reference Citation Analysis]
16 Poels TT, Vuijk FA, de Geus-Oei LF, Vahrmeijer AL, Oprea-Lager DE, Swijnenburg RJ. Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:6164. [PMID: 34944781 DOI: 10.3390/cancers13246164] [Reference Citation Analysis]
17 Pang Y, Zhao L, Shang Q, Meng T, Zhao L, Feng L, Wang S, Guo P, Wu X, Lin Q, Wu H, Huang W, Sun L, Chen H. Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 2021. [PMID: 34651226 DOI: 10.1007/s00259-021-05576-w] [Reference Citation Analysis]
18 Bernardes E, Caravan P, van Dam RM, Deuther-Conrad W, Ellis B, Furumoto S, Guillet B, Huang YY, Jia H, Laverman P, Li Z, Liu Z, Lodi F, Miao Y, Perk L, Schirrmacher R, Vercoullie J, Yang H, Yang M, Yang X, Zhang J, Zhang MR, Zhu H. Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharm Chem 2022;7:9. [PMID: 35471681 DOI: 10.1186/s41181-022-00162-3] [Reference Citation Analysis]
19 Backhaus P, Gierse F, Burg MC, Büther F, Asmus I, Dorten P, Cufe J, Roll W, Neri D, Cazzamalli S, Millul J, Mock J, Galbiati A, Zana A, Schäfers KP, Hermann S, Weckesser M, Tio J, Wagner S, Breyholz HJ, Schäfers M. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA. Eur J Nucl Med Mol Imaging 2021. [PMID: 34957527 DOI: 10.1007/s00259-021-05653-0] [Reference Citation Analysis]
20 Röhrich M, Syed M, Liew DP, Giesel FL, Liermann J, Choyke PL, Wefers AK, Ritz T, Szymbara M, Schillings L, Heger U, Rathke H, Kratochwil C, Huber PE, von Deimling A, Debus J, Kauczor HU, Haberkorn U, Adeberg S. 68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas - Imaging analysis and histological validation. Radiother Oncol 2021;160:192-201. [PMID: 33940087 DOI: 10.1016/j.radonc.2021.04.016] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Peng D, He J, Liu H, Cao J, Wang Y, Chen Y. FAPI PET/CT research progress in digestive system tumours. Dig Liver Dis 2021:S1590-8658(21)00380-7. [PMID: 34364808 DOI: 10.1016/j.dld.2021.07.011] [Reference Citation Analysis]
22 Gulhane AV, Chen DL. Overview of positron emission tomography in functional imaging of the lungs for diffuse lung diseases. Br J Radiol 2021;:20210824. [PMID: 34752146 DOI: 10.1259/bjr.20210824] [Reference Citation Analysis]
23 Sollini M, Kirienko M, Gelardi F, Fiz F, Gozzi N, Chiti A. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2021. [PMID: 34173007 DOI: 10.1007/s00259-021-05475-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
24 Kou Y, Jiang X, Yao Y, Shen J, Jiang X, Chen S, Lu H, Wang X, Zhao M, Xiao D, Shen T, Zhang W, Cheng Z. Physiological tracer distribution and benign lesion incidental uptake of Al18F-NOTA-FAPI-04 on PET/CT imaging. Nucl Med Commun 2022. [PMID: 35506283 DOI: 10.1097/MNM.0000000000001563] [Reference Citation Analysis]